CClinicalTrials.gg
AvailableNCT06757699Updated Jun 10, 2026

Evaluation of Different Serum Cartilage Biomarkers in the Acute Response to Walking and Cycling in Healthy Male Subjects

An expanded access record providing Walking and Cycling in Biochemical Markers, sponsored by Kocaeli University. Available at 2 sites in Turkey (Türkiye). Open to male participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Kocaeli University · Expanded access

Study type
Expanded access
Ages
20 Years to 35 Years
Sex
Male
01

Study summary

The effect of physical activity on serum cartilage biomarkers is largely unknown. This study is critical to increase our knowledge of the physiological cartilage response to activities of daily living and dynamic tasks by focusing on healthy recreationally active individuals, thus improving our understanding of the complex relationship between cartilage health and the loading that occurs during different types of loading.

Read the detailed description

Biomarkers can be used to monitor cartilage metabolism and serve as prognostic or diagnostic markers to detect changes in joint structure (8). Most of these biomarkers are essential components of the cartilage extracellular matrix (ECM). The measurement of cartilage biomarkers is based on the principle that osmotic and mechanical loading triggers the efflux of proteolytically produced ECM fragments into the synovial fluid and then out of the joint capsule. Thus, biomarker concentrations can be measured by immunoassays in synovial fluid, blood, and urine. Similarly, biomarker concentrations have been used to investigate the acute or long-term effects of exercise on articular cartilage health and metabolism.

The most studied serum cartilage biomarker is cartilage oligomeric matrix protein (COMP). COMP, also known as thrombospondin-5, is a pentameric glycoprotein composed of five identical subunits. The C-terminal end of each monomer interacts with numerous KDHM proteins, such as collagen II, collagen IX, matrilins, and proteoglycans (9). In addition, COMP affects collagen secretion and fibrillogenesis, thereby influencing the rate of fibril formation, organization, and diameter (10). Due to these interactions with other KDHM proteins, COMP has an important role in the assembly and structure of the cartilage matrix, determining its mechanical properties.

Based on these properties, COMP has been widely studied in terms of acute loading and has been shown to be mechanosensitive (11). Serum COMP levels have been found to vary between -16% and +39% after 30 min of moderate running interventions (12). However, no increase in serum concentration was detected in response to other acute exercises, such as knee flexion or repeated lumbar flexion/extension (13). This suggests that the acute serum COMP response is dependent on joint loading characteristics.

Other biomarkers of interest are proteolytic enzymes involved in the degradation of cartilage KDHM components. Matrix metalloproteinases (MMPs) are a family of enzymes that vary in substrate specificity and primary structure.

Some MMP family members play a role in both KDHM remodeling and pathological degradation. For example, MMP-3 (stromelysin) degrades most components of KDHM and activates other MMPs such as MMP-9 (gelatinase B), which itself plays an important role in the development of OA (14).

YKL-40 is another KDHM protein involved in cartilage pathogenesis. Although the function of YKL-40 has not been defined in detail, it has been shown to be involved in general tissue remodeling and inflammatory processes as a glycosylase (15). YKL-40 levels increase during joint inflammation, and resistin levels are also elevated by inflammatory stimuli. Resistin is an adipokine that was initially associated with obesity and insulin resistance in rodents.

The response of MMPs, YKL-40, and resistin concentrations to exercise has been previously investigated. Marathon running has been shown to increase serum MMP-3 (+142%), YKL-40 (+56%), and resistin (+107%) concentrations immediately after the marathon compared to baseline values (16).

Type II collagen is a major component of articular cartilage. The degradation of type II collagen occurs via the activity of collagenases and MMP-9. Coll2-1 is a specific peptide epitope located on the triple helix of type II collagen molecules and is a marker of cartilage degeneration.

The nitrated form of Coll2-1 is called Coll2-1 NO2 and reflects oxidative-related cartilage matrix degradation. Serum concentrations of Coll2-1 (-13%) and Coll2-1 NO2 (-19%) have been shown to decrease after a marathon run (17).

Nagaoka et al. (18) evaluated the cartilage collagen metabolism of athletes exposed to intense joint loading. They measured both type II collagen synthesis and degradation biomarkers in urine. The results showed that type II collagen degradation increased in response to endurance exercises that included intense joint loading, especially in athletes who performed frequent jumping movements such as volleyball, basketball and handball.

The aim of our study was to examine the acute effect of two commonly used exercise interventions (walking and cycling) on the correlation of serum biomarkers reflecting cartilage extracellular matrix metabolism, COMP, YKL-40, and MMP3.

02

Conditions studied

  • Biochemical Markers

Keywords

  • serum cartilage
  • Osteoblastic activity
  • Osteoclastic activity
03

In context

Lead sponsor

Kocaeli University is the lead sponsor of 210 studies on the registry; 38 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy male volunteers between the ages of 20-35
  • Those who do physical activity for at least 30 minutes two to three days a week
  • 17 healthy male individuals without any health problems will be included.

Exclusion criteria

Exclusion Criteria:

  • Those with acute or chronic injuries in their lower extremities
  • Those with musculoskeletal disorders in their lower extremities
  • Those who have undergone hip and/or knee surgery
  • Those with cardio-pulmonary problems that prevent them from exercising
05

Access details

Study type
Expanded access

Available treatment

  • OtherWalking

    Participants will perform 30 minutes of walking and cycling exercises. During the cycling and walking exercises, heart rate will be calculated using the Karvonen formula based on heart rate reserve. HRmax (maximum heart rate)=220-age HRR (%)(heart rate reserve)= (HR-HRrest)/(HRmax-HRrest)\*100 Blood samples will be collected from participants before starting the exercise, at the end of the 30-minute exercise session, and twice more at 30-minute intervals. The same participants will perform the cycling exercise half an hour later, and the same procedures will be applied.

  • OtherCycling

    Cycling

06

Where to request access

2 of 2 sites recruiting
  • Kocaeli University Faculty of Medicine Hospital
    Kocaeli, Turkey (Türkiye)
    Available
  • Sakarya University Applied Sciences Physiotherapy and Rehabilitation Application and Research Center
    Sakarya, Turkey (Türkiye)
    Available
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT06757699
Lead sponsor
Kocaeli University
Collaborators
Sakarya Applied Sciences University
Responsible party
Oguzhan Bahadir DEMIR (Assistant Professor, Kocaeli University) — Principal investigator
First posted
Jan 3, 2025
Last update
Jun 10, 2026

Study contacts

Oguzhan Demir
Contact
oguzhandemir@subu.edu.tr
+90264 616 1614
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion